Max Shulga gets the And-1
Spanish Prime Minister Pedro Sánchez recently said that his country was responsible for creating half of all new jobs in the eurozone, but is this true?View on euronews
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
Bayer BAYRY announced that it has won approval for pipeline drug elinzanetant in the UK for the treatment of moderate to severe vasomotor symptoms (VMS or hot flashes) associated with menopause. The Medicines and Healthcare products Regulatory Agency, a regulatory authority in the UK, has authorized the use of elinzanetant, under the brand name Lynkuet for the above-mentioned indication. Year to date, shares of Bayer have rallied 67% compared to the industry's gain of 2.7%. Image Source: Zacks Investment Research Elinzanetant is the first dual neurokinin (NK)-targeted therapy (NK-1 and NK- 3 receptor antagonist), which has been globally developed for the treatment of moderate to severe VMS associated with menopause or endocrine therapy for breast cancer, administered orally once daily. The marketing authorization in the UK marks the drug's first global approval. The approval was based on positive results from the late-stage studies OASIS-1, OASIS-2, and OASIS-3, which evaluated the efficacy and safety profile of elinzanetant. Results from the study showed that elinzanetant met all primary endpoints in all three studies and demonstrated a favorable safety profile. We note that elinzanetant is under regulatory review in the United States, countries of the European Union and other markets around the world. The approval of this hormone-free treatment is not only a transformative therapeutic advance for millions of women worldwide but also a compelling growth catalyst for Bayer's pharmaceutical division. As the first drug targeting both NK-1 and NK-3 receptors, it sidesteps the risks and contraindications associated with estrogen therapy, making it an attractive option for millions, including breast cancer survivors or women avoiding hormone-based interventions. Bayer's new products, such as Nubeqa and Kerendia, continue to maintain their impressive momentum in the Pharmaceutical division and offset the negative impact of a decline in Xarelto sales. The company is working to expand the labels of these key drugs, which should boost its top-line growth. Last month, the FDA expanded Nubeqa's label for a third indication for patients with advanced prostate cancer. The successful development of additional drugs is imperative for Bayer amid multiple challenges. BAYRY expects to launch two new drugs — elinzanetant and acoramidis, a drug for the treatment of a certain type of heart disease. The company also aims to strengthen its pharmaceutical pipeline. In 2021, Bayer acquired a clinical-stage biopharmaceutical company, Vividion Therapeutics, to expand into precision small-molecule therapeutics, primarily in oncology and immunology. BAYRY has expanded its pipeline in new modalities of cell therapy through the acquisition of BlueRock, and in gene therapy, through the AskBio buyout. BAYRY currently carries a Zacks Rank #1 (Strong Buy). A couple of other top-ranked stocks in the large-cap pharma sector are Novartis NVS and Johnson & Johnson JNJ, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.78 to $8.92 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.27 during the said timeframe. The stock has risen 30.2% so far this year. J&J's EPS estimate for 2025 has risen from $10.60 to $10.64 over the past 60 days, while that for 2026 has increased from $10.98 to $11.07 over the same timeframe. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
an hour ago
- Bloomberg
UK Plans New Measure to Boost EV Sales, Transport Secretary Says
The UK plans to introduce new incentives to make it cheaper for people to buy new electric vehicles as the Labour government attempts to phase out the sale of polluting cars. Speaking on Sunday, Transport Secretary Heidi Alexander confirmed she will be announcing new measures to boost sales of EVs this week but declined to directly address reports in the Telegraph and the Times that the incentives will include up to £700 million ($948 million) in new subsidies and grants to buyers to help offset costs.
Forbes
an hour ago
- Forbes
Real Madrid Cancels Expected First Team Transfer This Summer
Real Madrid has cancelled its expected pursuit of a former academy star that can return to the club ... More according to AS, which cited a report from transfer market expert Fabrizio Romano using anonymous sources. Real Madrid has cancelled its expected pursuit of a former academy star that can return to the club according to AS, which cited a report from transfer market expert Fabrizio Romano using anonymous sources. Madrid sold Nico Paz to Como last summer, after the Argentina international scored in the Champions League and therefore picked up a winners' medal in the continental competition to compliment others in La Liga and the Spanish Super Cup as Carlo Ancelotti sealed an impressive treble in 2024/2025. The moneyed Italians paid $6.5 million (€6.3 million) for 50% of Paz's rights yet Madrid retained buyback options across the next three seasons for youngster as he continues to learn under FC Barcelona legend Cesc Fabregas. To be more specific, Madrid can pay $8.3 million (€8 million) for him this summer, $9.4 million (€9 million) in 2026 or $10.4 million (€10 million) in 2027. In his last weeks before being replaced by Xabi Alonso and taking the Brazil national team post, Ancelotti tipped Paz to become the future of the club and admitted that Madrid had been keeping tabs on him. 'Nico Paz is a player we follow a lot. He's very good and he's very talented. This season away from Real Madrid is very good for him. We believe that he is a player who can be the future of Real Madrid,' Ancelotti explained, to Italian outlet Rai Radio. Because of this, there were reports that Paz could complete the 'Carvajal route' this summer, in being a La Fabrica product sold by his boyhood club yet returning to the first team after gaining valuable experience elsewhere. According to Romano, however, that won't be happening any time soon. 'Real Madrid confirmed to Como that they won't activate €8m buy back clause for Nico Páz, also formal communication has arrived,' Romano tweeted. 'Como plan to keep Paz this summer and then Real will have €9m buy back clause for next summer,' he then added. Real Madrid should still make improvements to the squad Be that as it may, Real Madrid will still look to make improvements to the first team squad by looking to sign another central defender and a left back in Alvaro Carreras from Benfica. As part of a major overhaul, two midfielders are reportedly sought in the medium term.
